Clinical Trial Update: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ANX005 in Participants With Warm Autoimmune Hemolytic Anemia (wAIHA) [Phase 2]

View source ↗

Summary

Phase 2 trial update on ANX005 assessing safety, tolerability, PK/PD in participants with warm autoimmune hemolytic anemia (wAIHA).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Warm Autoimmune Hemolytic Anemia

Drugs mentioned

• ANX005

Snippet

Sponsor: Annexon, Inc. | Conditions: Warm Autoimmune Hemolytic Anemia (wAIHA) | Phase 2 | Status: COMPLETED